Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 o For the transition period from to Commission file number: 001-39228 CLARITEV CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 84-3536151 (State or other ...

Claritev Corporation (NYSE:MPLN) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Shawna Gasik - Assistant Vice President, Investor Relations Travis Dalton - Chief Executive Officer Doug Garis - Chief Financial Officer Conference Call Participants Joshua Raskin - Nephron Research Daniel Grosslight - Citigroup Jessica Tassan - Piper Sandler Operator Hello all, and welcome to today's Claritev Corporation Fourth Quarter 2024 Earnings Call. My name is Drew, and I will be the op ...

MultiPlan Corporation (MPLN) came out with a quarterly loss of $5.14 per share versus the Zacks Consensus Estimate of a loss of $2.33. This compares to loss of $2.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -120.60%. A quarter ago, it was expected that this company would post a loss of $2.37 per share when it actually produced a loss of $1.85, delivering a surprise of 21.94%.Over the last four quarters, the company has ...

Claritev Q4 & FY 2024 Results and Business Update February 25, 2025 1 Disclaimer Forward-Looking Statements This presentation includes statements that express our management's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements". These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms "believes," "estim ...

EXHIBIT 99.1 Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025 NEW YORK, NY — February 25, 2025 — Claritev Corporation ("Claritev" or the "Company") (NYSE: MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2024. Chairman, CEO and President Travis Dalton said, "We are cel ...

MultiPlan Corporation (MPLN) - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days [1] - The stock price rallied 15.5% in the last trading session to close at $14.70, driven by notable trading volume [3] - The stock has gained 76.6% over the past four weeks [3] - The company is expected to post a quarterly loss of $2.33 per share, representing a year-over-year change of +2.9% [5] - Revenues are expected to be $236.74 million, down 3% from the year-ago quarter [5] - The recent price increase is attributed to investor optimism surrounding the company's decision to consolidate its cloud infrastructure on Oracle Cloud Infrastructure (OCI) as part of its digital transformation strategy [4] Medpace (MEDP) - The consensus EPS estimate for the upcoming report has increased by +0.9% over the past month to $2.97, representing a +20.7% change from the same period last year [2] - The stock closed the last trading session 0.3% higher at $352.01 [1] - Over the past month, the stock has returned 1.4% [1] Industry Context - MultiPlan belongs to the Zacks Medical Services industry [1] - Medpace is another stock in the same industry [1]

Debt and Capital Structure - As of September 30, 2024, the company's long-term debt totaled $4,569.060 million, a decrease from $4,600.030 million as of December 31, 2023[78] - The company purchased and canceled $21.1 million of Senior Convertible PIK Notes during the nine months ended September 30, 2024, resulting in a gain on extinguishment of $5.9 million[78] - The interest rate for Term Loan B was 9.57% as of September 30, 2024[78] - The company is exploring ways to optimize its capital structure to support its transformation into a data and technology-focused entity in healthcare[79] - The fair value of long-term debt as of September 30, 2024, was estimated at $3,059.946 million[88] - The company has irrevocable letters of credit totaling $7.9 million outstanding as of September 30, 2024, related to real estate lease agreements and a captive insurance subsidiary[94] Financial Performance - The company reported impairment charges of $361.6 million for goodwill and $1,434.4 million for long-lived intangible assets for the nine months ended September 30, 2024[91] - The Company reported a net loss of $391,450 thousand for the three months ended September 30, 2024, compared to a net loss of $24,145 thousand for the same period in 2023[102] - The net loss per share was $(24.25) for the three months ended September 30, 2024, compared to $(1.49) for the same period in 2023[102] - The weighted average number of shares outstanding was 16,143,520 for the three months ended September 30, 2024, slightly down from 16,161,095 in the same period of 2023[102] Stock and Legal Matters - The Company has authorized a stock repurchase program of up to $100.0 million, extended through December 31, 2024, with $25.6 million spent as of September 30, 2024[99] - Legal expenses related to ongoing litigation amounted to $23 thousand and $82 thousand for the three and nine months ended September 30, 2024, respectively[103] - The Company has accrued for legal fees and contingencies, reflecting significant management judgment in estimating potential liabilities[98] - The Company intends to vigorously defend against antitrust lawsuits centralized in the Northern District of Illinois[97] Other Financial Activities - The fair value of Private Placement Warrants and Unvested Founder Shares was recorded at $1,000 as of September 30, 2024, down from $477,000 as of December 31, 2023[82] - The company recognized losses of $87,000 related to the change in fair value of Private Placement Warrants and Unvested Founder Shares for the three months ended September 30, 2024[83] - The company received $9.8 million in recoveries from insurers related to a settled litigation during the three months ended September 30, 2024[96] - As of September 30, 2024, prepaid expenses from related parties were $6 thousand, down from $36 thousand as of December 31, 2023[104] Market Risks - There were no material changes in market risks as of September 30, 2024, compared to the 2023 Annual Report[211]

MultiPlan Corporation (NYSE:MPLN) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Shawna Gasik - AVP, IR Travis Dalton - CEO Doug Garis - CFO Conference Call Participants Joshua Raskin - Nephron Research Daniel Grosslight - Citigroup Jessica Tassan - Piper Sandler Madison Aron - JPMorgan Operator Hello and welcome to the MultiPlan Corporation Third Quarter 2024 Earnings Call. My name is Harry and I will be your operator today. All lines are currently in a listen-only mode a ...

MultiPlan Corporation (MPLN) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.37. This compares to loss of $2.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.94%. A quarter ago, it was expected that this company would post a loss of $1.60 per share when it actually produced a loss of $1.20, delivering a surprise of 25%.Over the last four quarters, the company has surpa ...

| --- | --- | |-------------------------------|-------| | | | | | | | | | | | | | | | | MultiPlan Q3 2024 Results and | | 1 Disclaimer Forward-Looking Statements This presentation includes statements that express our management's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements". These forwardlooking statements can generally be identified by the use of forward-lookin ...